Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

MoonLake Immunotherapeutics (MLTX) Return on Capital Employed (2021 - 2026)

MoonLake Immunotherapeutics' Return on Capital Employed history spans 6 years, with the latest figure at 73.0% for Q1 2026.

  • Quarterly Return on Capital Employed fell 3671.0% to 73.0% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 73.0% through Mar 2026, down 3671.0% year-over-year, with the annual reading at 60.35% for FY2025, 3052.0% down from the prior year.
  • Return on Capital Employed came in at 73.0% for Q1 2026, down from 65.48% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 131.73% in Q1 2022 to a low of 116.51% in Q3 2022.
  • The 5-year median for Return on Capital Employed is 36.28% (2025), against an average of 36.65%.
  • Year-over-year, Return on Capital Employed skyrocketed 13448bps in 2022 and then tumbled -22787bps in 2023.
  • MoonLake Immunotherapeutics' Return on Capital Employed stood at 86.69% in 2022, then soared by 88bps to 10.75% in 2023, then crashed by -180bps to 30.09% in 2024, then tumbled by -118bps to 65.48% in 2025, then decreased by -11bps to 73.0% in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Return on Capital Employed are 73.0% (Q1 2026), 65.48% (Q4 2025), and 58.94% (Q3 2025).